Your browser doesn't support javascript.
loading
Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelA.
van Dijk, Anneke D; Hoff, Fieke W; Qiu, Yihua; Gerbing, Robert B; Gamis, Alan S; Aplenc, Richard; Kolb, E Anders; Alonzo, Todd A; Meshinchi, Soheil; Jenkins, Gaye N; de Bont, Eveline S J M; Kornblau, Steven M; Horton, Terzah M.
Afiliação
  • van Dijk AD; Department of Pediatrics, University Medical Center Groningen, University of Groningen, Divison of Pediatric Oncology/Hematology, Groningen, The Netherlands.
  • Hoff FW; Department of Pediatrics, University Medical Center Groningen, University of Groningen, Divison of Pediatric Oncology/Hematology, Groningen, The Netherlands.
  • Qiu Y; Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.
  • Gerbing RB; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Gamis AS; COG Statistics and Data Center, Monrovia, California, USA.
  • Aplenc R; Department of Hematology-Oncology, Children's Mercy Hospitals and Clinics, Kansas City, Missouri, USA.
  • Kolb EA; Division of Pediatric Oncology/Stem Cell Transplant, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Alonzo TA; Nemours Center for Cancer and Blood Disorders, Alfred I. DuPont Hospital for Children, Wilmington, Delaware, USA.
  • Meshinchi S; Keck School of Medicine, University of Southern California, California, USA.
  • Jenkins GN; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • de Bont ESJM; Department of Pediatrics, Baylor College of Medicine/Dan L. Duncan Cancer Center and Texas Children's Cancer Center, Houston, Texas, USA.
  • Kornblau SM; Department of Pediatrics, University Medical Center Groningen, University of Groningen, Divison of Pediatric Oncology/Hematology, Groningen, The Netherlands.
  • Horton TM; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Proteomics Clin Appl ; 16(2): e2100072, 2022 03.
Article em En | MEDLINE | ID: mdl-34719869
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / NF-kappa B Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Child / Humans Idioma: En Revista: Proteomics Clin Appl Assunto da revista: BIOQUIMICA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda País de publicação: Alemanha
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / NF-kappa B Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Child / Humans Idioma: En Revista: Proteomics Clin Appl Assunto da revista: BIOQUIMICA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda País de publicação: Alemanha